Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity

Molecular Nutrition and Food Research

Volumn 55, Issue 8, 2011, Pages 1249-1265

  Kondratyuk, Tamara P ^a   Park, Eun Jung ^a   Marler, Laura E ^a   Ahn, Soyoun ^b   Yuan, Yang ^b   Choi, Yongsoo ^b   Yu, Rui ^b   van Breemen, Richard B ^b   Sun, Bin ^c   Hoshino, Juma ^c   Cushman, Mark ^c   Jermihov, Katherine C ^d   Mesecar, Andrew D ^d   Grubbs, Clinton J ^e   Pezzuto, John M ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c PURDUE UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

^e Kentucky   (United States)

Author keywords

Absorption; Caco 2 cells; Chemoprevention; Pleiotropic effect; SAR

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; AROMATASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NRH - QUINONE OXIDOREDUCTASE2; NRH QUINONE OXIDOREDUCTASE2; PROSTAGLANDIN SYNTHASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; CELL STRAIN CACO 2; DRUG ANTAGONISM; HUMAN; MOUSE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; AROMATASE INHIBITORS; CACO-2 CELLS; CYCLOOXYGENASE INHIBITORS; HUMANS; MICE; NF-KAPPA B; QUINONE REDUCTASES; RATS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 79961090100     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100122     Document Type: Article

References (95)

1. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V. et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220.
2. Francy-Guilford, J., Pezzuto, J., Mechanisms of cancer chemopreventive agents: a perspective. Planta Medica 2008, 74, 1644-1650.
3. Pezzuto, J. M., Resveratrol as an inhibitor of carcinogenesis. Pharm. Biol. 2008, 46, 443-573.
4. Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K. et al., Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell Biol. 2006, 26, 2887-2900.
5. Nho, C., Jeffery, E., The synergistic upregulation of phase II detoxification enzymes by glucosinolate breakdown products in cruciferous vegetables. Toxicol. Appl. Pharmacol. 2001, 174, 146-152.
6. Kennelly, E., Gerhäuser, C., Song, L., Graham, J. et al., Induction of quinone reductase by withanolides isolated from Physalis philidelphica (tomatillos). J. Agric. Food Chem. 1997, 45, 3771-3777.
7. Pezzuto, J. M., The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann. N. Y. Acad. Sci. 2011, 1215, 123-130.
8. Sun, B., Hoshino, J., Jermihov, K., Marler, L. et al., Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg. Med. Chem. 2010, 18, 5352-5366.
9. Pezzuto, J. M., in: Aggarwal, B. B., Shishodia, S. (Eds.), Resveratrol in Health and Disease, Marcel Dekker, Inc., New York 2006, pp. 233-383.
10. Pezzuto, J. M., Kondratyuk, T. P., Shalaev, E., in: Baer-Dubowska, W., Bartoszek, A., Malejka-Giganti, D. (Eds.), Carcinogenic and Anticarcinogenic Food Components, CRC Press, Boca Raton, FL 2006, pp. 239-282.
11. Harikumar, K. B., Aggarval, B. B., Resveratrol: amultitargeted agent for age-associated chronic diseases. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Cell Cycle 2008, 7, 1020-1035.
12. Calamini, B., Ratia, K., Malkowski, M., Cuendet, M. et al., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282.
13. Aggarwal, B. A., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P. et al., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24, 3-60.
14. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
15. Burns, J., Yokota, T., Ashihara, H., Lean, M., Crozier, A., Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 2002, 50, 3337-3340.
16. Rimando, A., Kalt, W., Magee, J., Dewey, J., Ballington, J., Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J. Agric. Food Chem. 2004, 52, 4713-4719.
17. Bhattacharya, A., Sood, P., Citovsky, V., The roles of plant phenolics in defence and communication during Agrobacterium and Rhizobium infection. Mol. Plant Pathol. 2010, 11, 705-719.
18. Hain, R., Bieseler, B., Kindl, H., Schroder, G., Stocker, R., Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol. 1990, 15, 325-335.
19. Takaoka, M., Resveratrol, a new phenolic compound, from Veratrum grandiflorum. J. Chem. Soc. Jpn. 1939, 60, 1090-1100.
20. Nonomura, S., Kanagawa, H., Makimoto A., Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-Jo-Kon. (Polygonum cuspidatum Sieb. et Zucc.). J. Pharm. Soc. Jpn. 1963, 83, 988-990.
21. Siemann, E. H., Creasy, L. L., Concentration of the phytoalexin resveratrol in wine. Am. Soc. Enol. Vitic. 1992, 43, 49-52.
22. Gronbaek, M., Deis, A., Sorensen, T. I., Becker, U. et al., Mortality associated with moderate intakes of wine, beer, or spirits. Br. Med. J. 1995, 310, 1165-1169.
23. Richard, J. L., Coronary risk factors. The French paradox. Arch. Mal. Coeur. Vaiss. 1987, 80, 17-21.
24. Stewart, J. R., Artime, M. C., O'Brian, C. A., Resveratrol: a candidate nutritional substance for prostate cancer prevention. J. Nutr. 2003, 133, 2440S-2443S.
25. Goldberg, D. M., Yan, J., Ng, E., Diamandis, E. P. et al., A global survey of trans-resveratrol concentrations in commercial wines. Am. J. Enol. Vitic. 1995, 46, 159-165.
26. Zern, T. L., West, K. L., Fernandez, M. L., Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J. Nutr. 2003, 133, 2268-2272.
27. Fitzpatrick, D. F., Hirschfield, S. L., Coffey, R. G., Endothelium dependent vasorelaxing activity of wine and other grape products. Am. J. Physiol. 1993, 265, H774-H778.
28. Lekakis, J., Rallidis, L. S., Andreadou, I., Vamvakou, G. et al., Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 2005, 12, 596-600.
29. Wang, Z., Zou, J., Cao, K., Hsieh, T. C. et al., Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int. J. Mol. Med. 2005, 16, 533-540.
30. Shen, M. Y., Hsiao, G., Liu, C. L., Fong, T. H. et al., Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 2007, 139, 475-485.
31. Meeran, S. M., Katiyar, S. K., Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci. 2008, 13, 2191-2202.
32. Clément, M. V., Hirpara, J. L., Chawdhury, S. H., Pervaiz, S., Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998, 92, 996-1002.
33. Hadi, S. M., Asad, S. F., Singh, S., Ahmad, A., Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life 2000, 50, 167-171.
34. Belleri, M., Ribatti, D., Nicoli, S., Cotelli, F. et al., Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3, 5, 4'-trimethoxystilbene. Mol. Pharmacol. 2005, 67, 1451-1459.
35. Surh, Y. J., Chun, K. S., Cha, H. H., Han, S. S. et al., Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 2001, 480-481, 243-268.
36. Dasgupta, B., Milbrandt, J., Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA 2007, 104, 7217-7222.
37. Leonard, S. S., Xia, C., Jiang, B. H., Stinefelt, B. et al., Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309, 1017-1026.
38. Manna, S. K., Mukhopadhyay, A., Aggarwal, B. B., Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 2000, 164, 6509-6519.
39. Athar, M., Back, J. H., Tang, X., Kim, K. H. et al., Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274-283.
40. Hu, X., Xuan, Y., Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 2008, 259, 127-137.
41. Raptis, S., Bapat, B., Genetic instability in human tumors. EX. 2006, 303-320.
42. Bhat, K. P. L., Kosmeder, J. W., 2nd, Pezzuto, J. M., Biological effects of resveratrol. Antioxid. Redox. Signal. 2001, 3, 1041-1064.
43. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W. et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
44. Wei, S., Kulp, S. K., Chen, C. S., Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem. 2010, 285, 9780-9791.
45. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.
46. Kraft, T. E., Parisotto, D., Schempp, C., Efferth, T., Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food Sci. Nutr. 2009, 49, 782-799.
47. Trela, B. C., Waterhouse, A. L., Resveratrol: isomeric molar absorptivities and stability. J. Agric. Food Chem. 1996, 44, 1253-1257.
48. Leiro, J., Alvarez, E., Arranz, J. A., Laguna, R. et al., Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J. Leukoc. Biol. 2004, 75, 1156-1165.
49. Surh, Y. J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768-780.
50. Kelloff, G. J., Sigman, C. C., Johnson, K. M., Boone, C. W. et al., Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 127-137.
51. Curtin, J., Donovan, M., Cotter, T., Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 2002, 265, 49-72.
52. Lee, S. K., Mbwambo, Z. H., Chung, H., Luyengi, L. et al., Evaluation of the antioxidant potential of natural products. Comb. Chem. High Throughput Screen. 1998, 1, 35-46.
53. Bhat, K. P., Pezzuto, J. M., Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci. 2002, 957, 210-229.
54. Martinez, J., Moreno, J. J., Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 2000, 59, 865-870.
55. Yen, G. C., Duh, P. D., Lin, C. W., Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic. Res. 2003, 37, 509-514.
56. Coussens, L. M., Werb, Z., Inflammation and cancer. Nature 2002, 420, 860-867.
57. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N. et al., Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273, 21875-21882.
58. Tsai, S. H., Lin-Shiau, S. Y., Lin, J. K., Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 1999, 126, 673-680.
59. Youn, H. S., Lee, J. Y., Fitzgerald, K. A., Young, H. A. et al., Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 2005, 175, 3339-3346.
60. Kundu, J. K., Shin, Y. K., Kim, S. H., Surh, Y. J., Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006, 27, 1465-1474.
61. Korzeniewski, N., Wheeler, S., Chatterjee, P., Duensing, A., Duensing, S., A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification-implications for chemoprevention. Mol. Cancer 2010, 9, 153-163.
62. Ciolino, H. P., Daschner, P. J., Yeh, G. C., Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58, 5707-5712.
63. Hayes, C. L., Spink, D. C., Spink, B. C., Cao, J. Q. et al., 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA 1996, 93, 9776-9781.
64. Peter Guengerich, F., Chun, Y. J., Kim, D., Gillam, E. M. T. S., Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutat. Res. 2003, 523-524, 173-182.
65. Neves, M. A., Dinis, T. C., Colombo, G., Sá e Melo, M. L., Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. Chem. Med. Chem. 2007, 2, 1750-1762.
66. Gonelli, A., Mischiati, C., Guerrini, R., Voltan, R. et al., Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. MiniRev. Med. Chem. 2009, 9, 498-509.
67. Jayatilake, G. S., Jayasuriya, H., Lee, E. S., Koonchanok, N. M. et al., Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod. 1993, 56, 1805-1810.
68. Schneider, Y., Vincent, F., Duranton, B., Badolo, L. et al., Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000, 158, 85-91.
69. Khanduja, K. L., Bhardwaj, A., Kaushik, G., Resveratrol inhibits N-nitrosodiethylamine-induced ornithine decarboxylase and cyclooxygenase in mice. J. Nutr. Sci. Vitaminol. 2004, 50, 61-65.
70. Chen, C., Kong, A. N., Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic. Biol. Med. 2004, 36, 1505-1516.
71. Prochaska, H. J., Santamaira, A. B., Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 1988, 169, 328-336.
72. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.
73. Athar, M., Back, J. H., Kopelovich, L., Bickers, D. R., Kim, A. L., Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009, 486, 95-102.
74. Fulda, S., Debatin, K. M., Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64, 337-346.
75. Corder, R., Crozier, A., Kroon, P. A., Drinking your health? It's too early to say. Nature 2003, 426, 119.
76. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., van Breemen, R. B., Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun. Mass Spectrom. 2003, 17, 307-313.
77. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. J. E., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
78. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M. et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
79. Kaldas, M. I., Walle, U. K., Walle, T., Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 2003, 55, 307-312.
80. Kang, S. S., Cuendet, M., Endringer, D. C., Croy, V. L. et al., Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB. Bioorg. Med. Chem. 2009, 17, 1044-1054.
81. Maiti, A., Cuendet, M., Croy, V. L., Endringer, D. C. et al., Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J. Med. Chem. 2007, 50, 2799-2806.
82. Hoshino, J., Park, E. J., Kondratyuk, T. P., Marler, L. et al., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
83. Song, L. L., Kosmeder, J. W., Lee, S. K., Gerhauser, C. et al., Cancer chemopreventive activity mediated by 4'-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res. 1999, 59, 578-585.
84. Kim, Y., Min, H. Y., Park, H. J., Lee, E. J. et al., Suppressive effects of nitric oxide production and inducible nitric oxide synthase (iNOS) gene expression by Calystegia soldanella methanol extract on lipopolysaccharide-activated RAW 264.7 cells. Eur. J. Cancer Prev. 2004, 13, 419-424.
85. Maiti, A., Cuendet, M., Kondratyuk, T., Croy, V. L. et al., Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J. Med. Chem. 2007, 50, 350-355.
86. Cao, H., Yu, R., Tao, Y., Nikolic, D., van Breemen, R. B., Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2011, 54, 230-235.
87. Li, Y., Shin, Y. G., Yu, C., Kosmeder, J. W. et al., Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism. Comb. Chem. High Throughput Screen. 2003, 6, 757-767.
88. Cuendet, M., Guo, J., Luo, Y., Chen, S. et al., Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res. 2010, 3, 221-232.
89. Marler, L., Maiti, A., Conda-Sheridan, M., Cushman, M. et al., Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives. Anticancer Res. 2010, 30, 4873-4882.
90. Kang, Y.-H., Pezzuto, J., in: Sies, H., Packer, L. (Eds.), Methods in Enzymology, Elsevier Science, San Diego 2004, pp. 380-415.
91. Buryanovsky, L., Fu, Y., Boyd, M., Ma, Y. et al., Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43, 11417-11426.
92. Choi, Y., Jermihov, K., Nam, S. J., Sturdy, M. et al., Screening natural products for inhibitors of quinone reductase-2 using ultrafiltration LC-MS. Anal. Chem. 2011, 83, 1048-1052.
93. Wenzel, E., Soldo, T., Erbersdobler, H., Somoza, V., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nut. Food Res. 2005, 49, 482-494.
94. Gehm, B. D., McAndrews, J. M., Chien, P-Y., Jameson, J. L., Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 14138-14143.
95. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., Klinge, C. M., Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141, 3657-3667.